AstraZeneca Pharma India Limited — Others, 07-01-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

AstraZeneca Pharma India Limited has announced a board meeting to discuss an order received from the Transfer Pricing Officer regarding adjustments to legacy issues under the Income Tax Act for the assessment year 2022-23. The company plans to challenge this order in an appellate forum once it receives the draft. While the specific financial implications remain undetermined, the proposed claim amounts to approximately ₹11.96 crores (excluding interest and penalties). Investors should monitor this situation closely, as it introduces potential risks related to financial exposure while also highlighting the company's commitment to addressing tax disputes.